Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial

被引：2

作者：

Rosellini, Matteo ^{[1
,2
]}

Tassinari, Elisa ^{[1
,2
]}

Marchetti, Andrea ^{[1
,2
]}

Mollica, Veronica ^{[1
,2
]}

Massari, Francesco ^{[1
,2
,3
]}

机构：

[1] Univ Bologna, Med Oncol Unit, IRCCS Azienda Osped, Bologna, Italy

[2] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[3] Univ Bologna, Med Oncol Dept, IRCCS Azienda Osped, Via Albertoni 15, Bologna, Italy

来源：

EUROPEAN UROLOGY | 2024年 / 85卷 / 01期

关键词：

D O I：

10.1016/j.eururo.2023.09.011

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：97 / 98

页数：2

共 50 条

[21] Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Bellmunt, Joaquim
Hussain, Maha
Gschwend, Jurgen E.
Albers, Peter
Oudard, Stephane
Castellano, Daniel
Daneshmand, Siamak
Nishiyama, Hiroyuki
Majchrowicz, Martin
Degaonkar, Viraj
Shi, Yi
Mariathasan, Sanjeev
Grivas, Petros
Drakaki, Alexandra
O'Donnell, Peter H.
Rosenberg, Jonathan E.
Geynisman, Daniel M.
Petrylak, Daniel P.
Hoffman-Censits, Jean
Bedke, Jens
Kalebasty, Arash Rezazadeh
Zakharia, Yousef
van der Heijden, Michiel S.
Sternberg, Cora N.
Davarpanah, Nicole N.
Powles, Thomas
LANCET ONCOLOGY, 2021, 22 (04): : 525 - 537
[22] Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
Armstrong, Andrew J.
Halabi, Susan
Eisen, Tim
Broderick, Samuel
Stadler, Walter M.
Jones, Robert J.
Garcia, Jorge A.
Vaishampayan, Ulka N.
Picus, Joel
Hawkins, Robert E.
Hainsworth, John D.
Kollmannsberger, Christian K.
Logan, Theodore F.
Puzanov, Igor
Pickering, Lisa M.
Ryan, Christopher W.
Protheroe, Andrew
Lusk, Christine M.
Oberg, Sadie
George, Daniel J.
LANCET ONCOLOGY, 2016, 17 (03): : 378 - 388
[23] Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Rini, Brian I.
Pal, Sumanta K.
Escudier, Bernard J.
Atkins, Michael B.
Hutson, Thomas E.
Porta, Camillo
Verzoni, Elena
Needle, Michael N.
McDermott, David F.
LANCET ONCOLOGY, 2020, 21 (01): : 95 - 104
[24] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trial
Motzer, Robert J.
Powles, Thomas
Burotto, Mauricio
Escudier, Bernard
Bourlon, Maria T.
Shah, Amishi Y.
Suarez, Cristina
Hamzaj, Alketa
Porta, Camillo
Hocking, Christopher M.
Kessler, Elizabeth R.
Gurney, Howard
Tomita, Yoshihiko
Bedke, Jens
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Apolo, Andrea B.
Choueiri, Toni K.
LANCET ONCOLOGY, 2022, 23 (07): : 888 - 898
[25] Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
Choueiri, Toni K.
McDermott, David F.
Merchan, Jaime
Bauer, Todd M.
Figlin, Robert
Heath, Elisabeth, I
Michaelson, M. Dror
Arrowsmith, Edward
D'Souza, Anishka
Zhao, Song
Roy, Ananya
Perini, Rodolfo
Vickery, Donna
Tykodi, Scott S.
LANCET ONCOLOGY, 2023, 24 (05): : 553 - 562
[26] Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial
Sun, Lu
Wang, Juan
Shao, Linlin
Yuan, Chenglu
Zhao, Hongguo
Li, Daqi
Wang, Zhencheng
Han, Panpan
Yu, Yafei
Xu, Miao
Zhao, Hongyu
Qiu, Jihua
Zhou, Hai
Liu, Xinguang
Hou, Yu
Peng, Jun
Hou, Ming
LANCET HAEMATOLOGY, 2021, 8 (04): : E289 - E298
[27] Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Motzer, Robert J.
Porta, Camillo
Vogelzang, Nicholas J.
Sternberg, Cora N.
Szczylik, Cezary
Zolnierek, Jakub
Kollmannsberger, Christian
Rha, Sun Young
Bjarnason, Georg A.
Melichar, Bohuslav
De Giorgi, Ugo
Gruenwald, Viktor
Davis, Ian D.
Lee, Jae-Lyun
Esteban, Emilio
Urbanowitz, Gladys
Cai, Can
Squires, Matthew
Marker, Mahtab
Shi, Michael M.
Escudier, Bernard
LANCET ONCOLOGY, 2014, 15 (03): : 286 - 296
[28] A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).
Procopio, Giuseppe
Claps, Melanie
Pircher, Chiara
Porcu, Luca
Sepe, Pierangela
Guadalupi, Valentina
De Giorgi, Ugo
Lolli, Cristian
Maruzzo, Marco
Nole, Franco
Iacovelli, Roberto
Masini, Cristina
Baldessari, Cinzia
Doni, Laura
Cusmai, Antonio
Gernone, Angela
Scagliarini, Sarah
Pignata, Sandro
De Braud, Filippo G.
Verzoni, Elena
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[29] A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer
Agarwal, Neeraj
Azad, Arun
Carles, Joan
Chowdhury, Simon
McGregor, Bradley
Merseburger, Axel S.
Oudard, Stephane
Saad, Fred
Soares, Andrey
Benzaghou, Fawzi
Kerloeguen, Yannick
Kimura, Akiko
Mohamed, Nehal
Panneerselvam, Ashok
Wang, Fong
Pal, Sumanta
FUTURE ONCOLOGY, 2022, 18 (10) : 1185 - 1198
[30] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer, Achim
Barlesi, Fabrice
Waterkamp, Daniel
Park, Keunchil
Ciardiello, Fortunato
von Pawel, Joachim
Gadgeel, Shirish M.
Hida, Toyoaki
Kowalski, Dariusz M.
Dols, Manuel Cobo
Cortinovis, Diego L.
Leach, Joseph
Polikoff, Jonathan
Barrios, Carlos
Kabbinavar, Fairooz
Frontera, Osvaldo Aren
De Marinis, Filippo
Turna, Hande
Lee, Jong-Seok
Ballinger, Marcus
Kowanetz, Marcin
He, Pei
Chen, Daniel S.
Sandler, Alan
Gandara, David R.
LANCET, 2017, 389 (10066): : 255 - 265

← 1 2 3 4 5 →